Janssen Pharmaceutica S.A./NV

Application No.: 3157/KOLNP/2009 Published on Nov. 13, Assigned to Janssen Pharmaceutica for 2-Aminopyrimidine Modulator (U.S. Inventors)
US Fed News Service, Including US State News; 12/14/2009; 377 words; ...Jing Liu, Neelakandha S. Mani, Michele C. Rizzolio...L. Wolin, all from U.S., have developed a 2...patent has been assigned to Janssen Pharmaceutica NV, Belgium. According to...patent was filed in U.S. under application No...

Patent No. 7,629,468 Issued on Dec. 8, Assigned to Janssen Pharmaceutica for Metabotropic Glutamate Receptor Antagonist (French Inventors)
US Fed News Service, Including US State News; 12/9/2009; 424 words; ...antagonist. The inventors were issued U.S. Patent No. 7,629,468 on Dec. 8. The patent has been assigned to Janssen Pharmaceutica NV, Beerse, Belgium. According to the abstract released by the U.S. Patent & Trademark Office...

Movetis Proves Gutsy with IPO: [euro]85M for Resolor, GI Pipeline.
BIOWORLD Today; 12/7/2009; 706 words; ...Brussels exchange is MOVE, and that's what the firm plans to do with Resolor...irritable bowel syndrome. The firm's portfolio is licensed from the Belgian-based firm Janssen Pharmaceutica NV and Raritan, N.J.-based Ortho...

Patent No. 7,626,036 Issued on Dec. 1, Assigned to Janssen Pharmaceutica for Bicyclic Heterocycles (Pennsylvania Inventors)
US Fed News Service, Including US State News; 12/2/2009; 385 words; ...modulators. The inventors were issued U.S. Patent No. 7,626,036 on Dec. 1. The patent has been assigned to Janssen Pharmaceutica NV, Beerse, Belgium. According to the abstract released by the U.S. Patent & Trademark Office...

Movetis Seeking [euro]112.5M: Is End to Europe's IPO Drought Near?
BioWorld International; 11/25/2009; 1014 words; ...International Correspondent Movetis NV is testing the mettle of...investors with the sector's first sizeable initial public...Belgium, was spun out from Janssen Pharmaceutica NV, a subsidiary of Johnson...next Wednesday. Europe's life sciences sector has...